Taken together with recent information about possible anti-inflammatory effect of GLP-1 we suggest that developing drugs targeting the incretin system may be potential additive therapy to IBD treatment resulting in less adverse effects and better clinical outcomes. This evidence concerns the gene GCG and inflammatory bowel disease.